Everolimus therapy for progressive adrenocortical cancer. - Wikidata - awgldk - TriplyDB

Everolimus therapy for progressive adrenocortical cancer.

Everolimus therapy for progressive adrenocortical cancer.

http://www.wikidata.org/entity/Q43478917

about

MicroRNA era: the importance for diagnosis and prognosis of adrenocortical tumors The challenge of developmental therapeutics for adrenocortical carcinoma A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.Adrenocortical carcinoma: the management of metastatic disease.Current management options for recurrent adrenocortical carcinoma.Genetics and epigenetics of adrenocortical tumors.Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma.MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy.Diagnosis, treatment and outcome of adrenocortical cancer.Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.P53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model.Clinical Case of Metastatic Adrenocortical Carcinoma With Unusual Evolution: Review the Literature The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells.Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.

P2860

Q27027738-09D42994-7ADA-4E91-871C-B77D3DA1FE8A Q28072970-55B51FE8-5367-49DE-AEAB-822C337FB86D Q34017912-2C251232-869D-4852-A997-3267C7E101A3 Q36081865-14515BFA-7145-4E3D-A2A2-D866BD7FF30C Q36925876-178B66D2-3EC6-40D1-BFD2-9EFC9C0AC133 Q38162079-EDCBFF66-917D-4C02-AF23-9DA6FE390C06 Q38253996-5C2AB37D-D5AB-4239-AA80-FCC5BFF813F2 Q38258284-CB4C4466-1ABD-4639-AE1E-788D2FFD54F1 Q38358503-3A94D5E9-493A-497C-A885-221424D91EFA Q38713191-48924D32-8926-4BF1-A589-FE4E7D7D437C Q38860968-7A30D57B-4CD1-4ADD-9D3A-0A1A8D1FB2CB Q41863971-6A408AC5-6CE1-4202-96E7-FD55BF856462 Q52673059-6C8CE82A-5429-4A43-B7ED-5326C9EF69B6 Q53251508-7E3BC135-E427-4EA1-AC59-4B4B7B996FCD

P2860

Everolimus therapy for progressive adrenocortical cancer.

http://www.wikidata.org/entity/Q43478917

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Everolimus therapy for progressive adrenocortical cancer.

@en

Everolimus therapy for progressive adrenocortical cancer.

@nl

type

label

Everolimus therapy for progressive adrenocortical cancer.

@en

Everolimus therapy for progressive adrenocortical cancer.

@nl

prefLabel

Everolimus therapy for progressive adrenocortical cancer.

@en

Everolimus therapy for progressive adrenocortical cancer.

@nl

P1433

Q43478917-20ABEB65-B474-418F-B94B-DC5EC6A8F13F

P1476

Q43478917-2F2D6906-683C-4FCD-85F3-37B338ADE2BD

P2093

Q43478917-51E1558B-2A3A-4491-862E-F1885E74C65F

Q43478917-5FA29A68-86C5-46D6-8591-9145E3FCFE13

Q43478917-6A39411D-A109-4C82-9D59-683508B93EF8

Q43478917-7354717D-6711-4036-BDD0-27F81FCF3868

Q43478917-9361CD85-A034-4712-8736-1713C0D8AC08

Q43478917-FA7F2017-0471-4F43-BD60-11A9CD8143D8

P2860

Q43478917-01D88C2C-E0A4-4F23-89AD-6E89F4A5ABF9

Q43478917-069F2896-4837-40F2-B1E0-9E85368077C2

Q43478917-0941E360-F7D2-436B-A001-E369F51D768B

Q43478917-2251960D-D6AD-44DF-8E26-5B2E9FF5107C

Q43478917-23E8F5DB-9E8B-4555-98C5-FDB36B60CE22

Q43478917-249E7849-2C62-4D10-B27C-6C587188F395

Q43478917-258EEB14-0D48-41F6-9B37-914411ECA13E

Q43478917-26E5D440-22C2-4518-84B3-9CE0257C64C3

Q43478917-2806CA66-3287-44A1-9F8F-48C6DD0AE1A2

Q43478917-3717CD32-A69F-4BCE-A75E-2C008CF7A88C

P2888

Q43478917-A51A92A7-3F38-40F9-A77C-9112E38DF86E

P304

Q43478917-A215D056-3460-46C9-B51D-326A0AD6611E

P31

Q43478917-C56229D2-6450-49B0-B98A-9E56CECC6902

P356

Q43478917-69B41CE5-E5EC-4D0A-B0DE-58B7167DB351

P433

Q43478917-AAE1C803-DBDC-4BCA-95E0-93459E7DFACF

P478

Q43478917-75854004-7991-4A11-A4D2-40E577616A00

P577

Q43478917-490DD467-AF8E-4540-BAF4-EEED33521DB5

P6179

Q43478917-8B01ADF3-C3EE-46E9-B360-3275864211FE

P698

Q43478917-C3642979-CB99-4857-B89F-D059E3EA513C

P356

S12020-013-9878-1

P1433

P1476

Everolimus therapy for progressive adrenocortical cancer.

@en

P2093

A B Grossman

http://www.w3.org/2001/XMLSchema#string

A Salmon

http://www.w3.org/2001/XMLSchema#string

D Barak

http://www.w3.org/2001/XMLSchema#string

D J Gross

http://www.w3.org/2001/XMLSchema#string

M Fraenkel

http://www.w3.org/2001/XMLSchema#string

M Gueorguiev

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant mitotane treatment for adrenocortical carcinoma

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.

Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.

Marginal increase of sunitinib exposure by grapefruit juice.

Clinical pharmacokinetics of tyrosine kinase inhibitors.

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.

Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.

P2888

s12020-013-9878-1

P304

187-192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12020-013-9878-1

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1041176115

http://www.w3.org/2001/XMLSchema#string

P698

23417626

http://www.w3.org/2001/XMLSchema#string